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Background
The current recommendations for early Rheumatoid
Arthritis (eRA) management focus on achieving clinical
remission as soon as possible with an early and intensive
treatment. Interventions tailored to prospectively identify
barriers for the provision of early and intensive treatment
are more likely to improve healthcare professionals’
adherence to treatment guidelines and to change practice
in order to reflect current best evidence. The objective of
this study was to explore the barriers and their relative
importance for the provision of intensive combination
treatment strategies (ICTS) in eRA from the healthcare
professionals’ perspective.
Materials and methods
Individual semi-structured interviews were conducted
with 26 rheumatologists and 6 nurses participating in
the CareRA trial. The CareRA trial is a Flemish multi-
centre RCT comparing different ICTS for eRA based on
synthetic disease-modifying antirheumatic drugs in com-
bination with a step-down glucocorticoid bridging
scheme. Each interview was audio-taped, transcribed lit-
erally and thematically coded using the constant com-
parative method. The barriers identified from the
interviews were incorporated in a Maximum Difference
Scaling (MDS) survey, which was completed by 66
Flemish rheumatologists (response rate 44%). The MDS
survey included 25 choice sets, each of which contained
a different set of 4 barriers. In each choice situation, the
rheumatologists were asked to select the most important
barrier in their opinion. The mean relative importance
score for each barrier was calculated using hierarchical
Bayes modeling (Sawtooth Software’s SSI Web platform,
version 8.2.0).
Results
An initial list of 25 barriers emerged out of the inter-
views, including 10 treatment-, 4 healthcare professional-
, 4 patient- and 7 environment-related barriers. The most
important barriers identified from the MDS survey were:
contraindication for some patients (e.g., patients with
comorbidities, older patients); increased risk of side
effects and related complications; and having to deal with
patients’ resistance.
Conclusions
Concerns regarding the suitability of ICTS for the indi-
vidual patient and the complexity of prescribing a com-
bination therapy including glucocorticoids were the
most important barriers, highlighting the complexity of
implementing ICTS for eRA in daily clinical practice.
Implementation strategies for ICTS in daily practice
should focus on physicians’ familiarity with the treat-
ment strategies and patient education.
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